Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19)

Study Overview
=================
Brief Summary
-----------------
The investigators will study nasopharunx microbiota composition, RNA sequences and in vitro cytokines production by peripheral blood cells of COVID-19 patients (both mild-moderate and severe cases) (comparing with convalescent patients and healthy controls).

Detailed Description
-----------------
The investigators will compare study parameters (basal) between mild-moderate and severe COVID-19 patients and with other study groups (i.e. convalescent and healthy controls). Nasopharunx microbiota dysbiosis, in vitro cytokines production profile, and peripheral blood flocytometric results of the four study groups will be compared. In vitro cytokines production will be studied and compared in Nill (No antigens) and Mitojen (Cocktail of antigens) pre-prepared test tubes.

Official Title
-----------------
TUSEB-Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19)

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to give a written consent Exclusion Criteria: In ability to give a written consent Using of medications that affect the results of study parameters Presence of malignancy or tuberculosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Mild-Moderate COVID-19 | Other: Observation<br>* The study parameters will be obtained at the time of recuirement (Basal)<br>|
| 2<br>Severe COVID-19 | Other: Observation<br>* The study parameters will be obtained at the time of recuirement (Basal)<br>|
| 3<br>Convalsent (COVID-19) | Other: Observation<br>* The study parameters will be obtained at the time of recuirement (Basal)<br>|
| 4<br>Healthy persons | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of peripheral blood RNA microarray assay | Four study groups, microarray Analysis . | First day | 
| Determination of nasopharunx Microbiota analysis | Four study groups, metagenomic analysis, to determine abundance and decrease of some species. | 1st day | 
| Determination of in vitro cytokines production | IL-2, IL-7, IL-10, granulocyte-colony stimulating factor, interferon-p inducible protein 10, monocyte chemo-attracting protein 1, macrophage inflammatory protein 1-α and tumor necrosis factor-α in Nill (no angijen) and Mitojen (Cocktails of antigens)tubes (between 4 study groups) | First day | 
| Determination of peripheral blood cytometry | Four study groups, peripheral blood cytometry; CD3, CD4, CD8, and CD45 rates. | First day | 
| Relation between study parameters | determining the realtion between microbiotme dysbiosis, in vitro cytokines production and peripheral leymphocytes (CD3,CD4, CD8, and CD45) rates and the severity of COVID-19( if any) | First day parameters |